CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.
Conditions
- Autoimmune Hemolytic Anemia
- CD19/BCMA CAR T-cells
- Universal Allogeneic CAR T-cells
Interventions
- BIOLOGICAL: universal allogeneic anti-CD19/BCMA CAR T-cells
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Collaborators